Else Nutrition Advances U.S. Market Entry with FDA Guidance on Protein Standards

On March 10, 2026, Else Nutrition Holdings Inc. announced a significant regulatory advancement that could enhance its entry into the U.S. infant formula market. The U.S. Food and Drug Administration (FDA) has formally recognized the Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance as an active topic within its regulatory agenda. This development is expected to provide clearer guidelines for novel infant formulas, especially those utilizing plant-based proteins.

FDA Guidance Signals Shift in Infant Formula Regulation

The updated PER guidance offers a pathway for companies like Else Nutrition to demonstrate the protein quality of their products. Historically, existing protein standards have been seen as outdated, creating regulatory uncertainty for manufacturers of innovative formulas. The FDA’s advancement in PER guidance aims to clarify study design and expectations, enabling a more transparent approach to validating protein quality.

For Else Nutrition, this shift reduces a key regulatory risk associated with the commercialization of its plant-based infant formula. The clarity provided by the FDA is expected to enhance the company’s ability to navigate the regulatory landscape, which is crucial for bringing its products to market.

Aligning with Federal Initiatives for Market Modernization

The U.S. infant formula market, one of the largest globally, has long been criticized for its limited protein options. Federal agencies, including Congress, have stressed the importance of expanding consumer choices with non-dairy, non-soy, and plant-based alternatives. This sentiment was echoed by Else Nutrition in a release from June 2025.

The FDA’s work on PER guidance aligns with ongoing federal efforts, such as Operation Stork Speed, which aims to modernize the regulatory frameworks governing infant formula for the first time since 1998. This initiative seeks to streamline regulations and improve clarity around product approvals, ultimately benefiting both manufacturers and consumers.

As most competitors continue to rely on conventional dairy or soy proteins, the new PER methodology is poised to support the introduction of alternative protein sources. Else Nutrition believes this regulatory modernization positions it favorably to leverage increasing consumer demand for clean-label and plant-based nutrition.

Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition, remarked on the implications of the FDA’s progress. “The FDA’s progress on PER guidance is a meaningful inflection point for Else Nutrition. As clarity increases around the scientific and procedural standards required for novel infant formulas, our regulatory roadmap becomes sharper and more predictable,” Yitzhak stated. This development enhances the company’s confidence in the commercial potential of its infant formula program in the U.S.

With expectations for growing competition and innovation in the U.S. formula market, Else Nutrition is well-positioned to benefit from these structural changes. The company aims to capitalize on the evolving regulatory landscape to facilitate its entry into the multi-billion-dollar market.

For more information on Else Nutrition’s innovative approach to infant nutrition, visit www.elsenutrition.com.

Else Nutrition Holdings Inc. is committed to developing clean, plant-based food and nutrition products for infants, toddlers, and children. Since launching its plant-based complete nutrition for toddlers, the company has garnered significant consumer support and achieved impressive sales growth.

As the regulatory environment continues to evolve, Else Nutrition remains optimistic about its future in the changing landscape of infant nutrition, poised to meet consumer needs for healthier, plant-based alternatives.